Evaluating the Potential and Limitations of Liquid Biopsies in Cancer Screening
Liquid biopsies offer a promising avenue for early cancer detection, but current evidence is insufficient to confirm their effectiveness and safety. Experts call for more rigorous research before widespread adoption.
Liquid biopsies, which analyze blood samples to detect circulating DNA, proteins, and other biomarkers associated with various cancers, are garnering significant interest for their potential to identify tumors that are otherwise difficult to detect early. Several laboratory-developed multi-cancer detection (MCD) tests—such as OneTest, Galleri, OncoSeek, and the newly launched Cancerguard—are available for purchase online with a doctor's note, although none have received approval from the U.S. Food and Drug Administration (FDA). These tests are priced around $950 and aim to enhance early detection, especially for cancers lacking standard screening options, which account for up to 70% of cancer-related deaths.
However, the effectiveness of these tests in real-world settings remains uncertain. A comprehensive review of 20 studies involving over 109,000 individuals revealed significant variability in test accuracy depending on the type of cancer, the study design, and the population tested. Currently, there's a lack of controlled, clinical trials demonstrating that MCD tests improve cancer detection rates, reduce mortality, or enhance quality of life. The primary concern is the potential for false positives, which can lead to unnecessary invasive procedures, anxiety, and stress for healthy individuals.
Experts emphasize that, despite the technological advancements, the scientific community needs more rigorous research to establish the clinical benefits of liquid biopsies. The current evidence does not sufficiently weigh the benefits against the harms, and insurance coverage for such tests is often unavailable.
In conclusion, while liquid biopsies hold promise for revolutionizing cancer screening, their widespread use should be approached with caution. Additional controlled studies are essential to determine their true utility and to develop guidelines for their integration into clinical practice.
source: https://medicalxpress.com/news/2025-09-liquid-biopsies-cancer-screening.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Impact of Prenatal PFAS Exposure on Infant Immunity and Long-term Health
This study reveals how prenatal exposure to PFAS chemicals can alter infant immune development, potentially affecting vaccine responses and increasing risks of allergies and autoimmune diseases.
Long-term Study Reveals Disease Risk Surpasses Remission Status in Determining Transplant Outcomes for AML Patients
A groundbreaking long-term study shows that genetic risk factors, not remission status, are key to AML transplant success, challenging current treatment standards and emphasizing personalized approaches.
Innovative Urine Test Detects Bladder Cancer Through Tumor DNA Analysis
A novel urine-based test utilizing genome-wide DNA methylation mapping offers a highly accurate, non-invasive method for detecting bladder cancer early, potentially transforming diagnostic approaches.
New Insights into Immune Mechanisms Preventing Neurological Damage from Oropouche Virus
New research uncovers how the immune system's early response, particularly B cells and MyD88 protein, prevents neurological damage from Oropouche virus, offering hope for future therapies. Read about the latest findings that could aid in developing vaccines and treatments.